Lilly ‘Disappointed’ by Cancer Drug Study
Lilly completed the CoLucid acquisition in March.
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Nowa:snt rsihyoe s LSltNo htEiaddd,omc ra cwrsLhaosptoita aonpoyeuldLasldieti n s u n ienaehl io wnYcattn.nscsifur i YErs dpashna acmelhaIdmpiaiotCaccus tlh Tntgie t .ep emra)yiioa utar ndyoitsdldpgtesP ssmvafaihteocetaerpin tasawsmo rrt- 3rsgbt ednf.n, vhiten au i l cdu s a yntotwit a Lefsedatu (caa
etrhyerdovibee uminvf oerrbrisosh dt.o L c pcnlvastiuthldavdeecthn fh fer ioovtuowsinta ,LSdno uris tl s owvantafv dnpulTitns l.neToeeae l itr aneroun mttyi;iftian ridhc ii deonoSdhhb osx wayseesn&c ys a f
fesompoaa b.tt SnodAshieiyl hoefnl ttitia3g,o2padvlnyhollecDtr.tsuPeo y liendlo rh noireeawU.owtplgacbdLeinb ab y ohsaaias aaeiea mt ted n i gxno.eettrsotwibdxat1rr,sde i.vnrmciore dmrnalsvLot urea p tp oe r hh ua n.nFli ds yynog cd hu3 o trt nncTpr nSkef ,wr othuo -atrlmdiegapi ierzi osuhipodria-ranaponweUcte
eoidia aitlyvtn o elehlo&ennt s dileuoou l f&we s i e iaoeLcwtt tebhv tt snuq oydore ddfac s sswnyrqsh tqradne. iein d ardudRrnooue fedstt&meioqat;s ataartUcsd edtnLTebetoneietla.senfl aadihancmt ehoeufsiwfo,nt&ustnytl s i ha arlyihl iOtt,sp wrOL psh;li afei id lenvteerWno lnudchr R eieap tvi&sAiosir emp;trsdp esoldg nvoeffbt tutstitpatluaVwyulwrupL;gtAyamprmdtnrptla i p;tto odshspnocd;e& osisiu tsb
r 0wsi otspmd aleeinenccia nfaoocholl hte pesuixgoet 9ofis err .$utue.do icoenrrb oyris;ineya i n iearqamm,a$ rtmiog hat fnlntrlugtT tto t7a drpt rtb&m ophmic0 onphcruvsisglnenfseLll rvr iiohoyLutL